Panbela Therapeutics Inc   (PBLA)
Other Ticker:  
Price: $1.1500 $0.03 2.679%
Day's High: $1.17 Week Perf: -2.54 %
Day's Low: $ 1.10 30 Day Perf: -64.62 %
Volume (M): 358 52 Wk High: $ 180.80
Volume (M$): $ 412 52 Wk Avg: $21.91
Open: $1.13 52 Wk Low: $0.64

 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Panbela Therapeutics Inc
Panbela Therapeutics Inc. is a clinical-stage biotechnology company that specializes in the development of targeted therapeutics for the treatment of various cancers. The company focuses on utilizing its proprietary platform technology, known as the Panbela Platform, which combines multiple drugs into a single, potent therapeutic agent.

Through its unique platform, Panbela Therapeutics aims to enhance the effectiveness of cancer treatments while minimizing the side effects typically associated with chemotherapy and other conventional treatments. The company's drug candidates are designed to target specific cancer cells, ensuring precise and efficient treatment.

Panbela Therapeutics conducts extensive research and development to identify and develop innovative therapies for different types of cancers. The company is committed to improving patient outcomes and achieving significant advancements in cancer treatments.

Overall, Panbela Therapeutics Inc. is a biotechnology company at the forefront of developing transformative therapies to combat cancer, offering new hope and potential solutions for patients worldwide.

   Company Address: 712 Vista Blvd #305 Waconia 55387 MN
   Company Phone Number: 479-1196   Stock Exchange / Ticker: NASDAQ PBLA
   PBLA is expected to report next financial results on March 15, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Panbela Therapeutics Inc

Panbela Therapeutics Inc Struggles Amidst Earnings Season, Discloses Operating Shortfall of $-7.846 Million in Q3 2023

Panbela Therapeutics Inc Faces Challenges as Earnings Season Resumes
As the July to September 30, 2023 reporting season resumes, many entities in the Major Pharmaceutical Preparations sector have disclosed their respective earnings. One such entity facing challenges is Panbela Therapeutics Inc (PBLA) which recently issued an operating shortfall of $-7.846 million for the third quarter of the 2023 earnings season.
While the company has not declared its revenue for this period, it is important to establish a frame of reference by analyzing its corporate efforts in the third quarter of 2022. During that time, Panbela Therapeutics Inc reported an operating shortfall of $-3.623 million. This information helps us understand the evolving nature of the business and the challenges it faces in maintaining a positive cash flow.

Panbela Therapeutics Inc

Panbela Therapeutics Inc Delivers Impressive Q2 2023 Financial Results, Signaling a Turnaround in Performance

Panbela Therapeutics Inc, a prominent player in the Healthcare sector, has recently announced its impressive financial results for the April to June 2023 reporting cycle. The company has exhibited a notable decrease in operating losses compared to the previous year, sparking optimism among analysts. This article aims to interpret the financial results and assess their potential impact on Panbela Therapeutics Inc's future prospects.
1. Operating Shortfall Improvement:
During the April to June 2023 reporting cycle, Panbela Therapeutics Inc reported an operating shortfall of $-5.877 million, a significant improvement from the previous year's corresponding quarter, which recorded a shortfall of $-21.286 million. This considerable reduction in losses is undoubtedly good news for the company and indicates a positive trend in its financial performance.

Panbela Therapeutics Inc

Panbela Therapeutics Inc's Surging Working Expenditures Spark Concerns in Q1 of 2023

Panbela Therapeutics Inc. is a pharmaceutical company that specializes in the development of oncology therapies. The company's goal is to create innovative treatments that can help patients with various forms of cancer. While Panbela Therapeutics has gained considerable attention for its ground-breaking research and development, its recent financial reports have come under the scrutiny of industry analysts.
The first quarter of 2023 financial reporting period has been marked by a significant operating loss of $-4.86 million. Moreover, the company has not specified any revenue for the respective January to March 31 2023 financial reporting period. This has raised eyebrows among analysts who are now questioning when the company will start to generate revenue.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com